Monoclonal antibodies
At OBT, we collaborate with world leaders in the field to develop antibodies specific to the unique cancer targets identified by us. The monoclonal antibodies incorporated into our antibody-drug conjugates (ADCs) are engineered to bind specifically to highly expressed proteins on the cancer cell membranes and selected specifically for optimum performance in delivering toxins to cancer cells.
Bispecific antibodies
At OBT, we collaborate with world leaders in the field to develop antibodies specific to the unique cancer targets identified by us. The monoclonal antibodies incorporated into our antibody-drug conjugates (ADCs) are engineered to bind specifically to highly expressed proteins on the cancer cell membranes and selected specifically for optimum performance in delivering toxins to cancer cells.
